<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="438">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155449</url>
  </required_header>
  <id_info>
    <org_study_id>PEC19132</org_study_id>
    <nct_id>NCT05155449</nct_id>
  </id_info>
  <brief_title>Probiotic Intervention for Gut Function</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Effect of Probiotics on Gut Function in Healthy Chinese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probi AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Probi AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of probiotics on gut function in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bowel movements</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reduction of the number of bowel movements</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gut Function</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsule per day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 65 years&#xD;
&#xD;
          -  BMI between 18.5 and 27.9 kg/m²&#xD;
&#xD;
          -  Subjects having ≥ 3 bowel movements per day&#xD;
&#xD;
          -  Subject not satisfied with their bowel habits&#xD;
&#xD;
          -  Subject having frequent stools during more than 4 weeks&#xD;
&#xD;
          -  For women: Non menopausal with the same reliable contraception since at least 3 cycles&#xD;
             before the beginning of the study and agreeing to keep it during the entire duration&#xD;
             of the study&#xD;
&#xD;
          -  Subjects agreeing to keep their dietary and life habits unchanged throughout the study&#xD;
&#xD;
          -  Good general and mental health within the opinion of the investigator&#xD;
&#xD;
          -  Able and willing to participate to the study by complying with the protocol procedures&#xD;
             as evidenced by a dated and signed ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suffering IBS according to Rome IV criteria, chronic intestinal disease,&#xD;
             immunodeficiency disorder or immunosuppressive treatment&#xD;
&#xD;
          -  Clinically significant frequent constipation or diarrhea at the screening visit as&#xD;
             judged by the Investigator&#xD;
&#xD;
          -  Suffering from a severe chronic disease or GI disorders found to be inconsistent with&#xD;
             the conduct of the study by the investigator&#xD;
&#xD;
          -  Intake of antibiotics within 8 weeks prior to the start of the study&#xD;
&#xD;
          -  With regular intake of probiotics within four weeks prior to V1 visit&#xD;
&#xD;
          -  Under treatment or dietary supplement which could significantly affect parameter(s)&#xD;
             followed during the study according to the investigator or stopped in a too short&#xD;
             period before the V1 visit&#xD;
&#xD;
          -  Suspected alcohol or substance abuse&#xD;
&#xD;
          -  Use of medications other than contraceptives or prescribed medication after consulting&#xD;
             with the investigator&#xD;
&#xD;
          -  History of any clinically significant disease or disorder which, in the opinion of the&#xD;
             Investigator, may either put the subject at risk if participating in the study, or&#xD;
             influence the results or the subject´s ability to participate in the study&#xD;
&#xD;
          -  With a known gluten intolerance, milk protein allergy&#xD;
&#xD;
          -  With a known or suspected food allergy or intolerance or hypersensitivity to any of&#xD;
             the study products' ingredients&#xD;
&#xD;
          -  Pregnant or lactating women or intending to become pregnant within 3 months ahead&#xD;
&#xD;
          -  With significant change in food habits or in physical activity in the 3 months before&#xD;
             the V1 visit&#xD;
&#xD;
          -  With a personal history of anorexia nervosa, bulimia or significant eating disorders&#xD;
             according to the investigator&#xD;
&#xD;
          -  Having a lifestyle deemed incompatible with the study according to the investigator&#xD;
&#xD;
          -  Currently participating in another clinical study, has done so in the past 30 days or&#xD;
             being in the exclusion period of a previous clinical trial&#xD;
&#xD;
          -  Under legal protection (guardianship, wardship) or deprived from his/her rights&#xD;
             following administrative or judicial decision&#xD;
&#xD;
          -  Presenting a psychological or linguistic incapability to sign the informed consent or&#xD;
             Investigator considers the subject unlikely to comply with study procedures,&#xD;
             restrictions and requirements&#xD;
&#xD;
          -  Impossible to contact in case of emergency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiangjun Meng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai 9th People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiangjun Meng, MD</last_name>
    <phone>+86 021-53315134</phone>
    <email>xiangjunmeng@aliyun.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

